Your prediction
Pros and Cons of Eagle Pharmaceuticals Inc in the next few years
Pros
?
C******** o* t** e**********
?
B****
?
S********** s********
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Eagle Pharmaceuticals Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Eagle Pharmaceuticals Inc | - | - | - | - | - | - | - |
| Pacira Pharmaceuticals | -1.960% | -3.774% | -8.108% | -1.923% | -5.556% | -40.000% | -57.851% |
| Corcept Therapeutics Inc. | -1.170% | 2.456% | 27.268% | 54.277% | 40.333% | 237.887% | 427.253% |
| Supernus Pharmaceuticals | -1.450% | 10.695% | -0.481% | 18.966% | -3.721% | 43.750% | 99.038% |
Comments
Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) was downgraded by analysts at Piper Sandler from a "neutral" rating to an "underweight" rating.
Show more
Ratings data for EGRX provided by MarketBeat

